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angioplasty
Abstract
Purpose: To assess the relationship between plasma homocysteine levels and restenosis after
femoropopliteal percutaneous transluminal angioplasty.Methods: Over a 10-month period, 128
consecutive, symptomatic patients (72 men; median age 70 years) having successful femoropopliteal
angioplasty for atherosclerotic occlusive disease were prospectively enrolled in the study. Plasma
homocysteine levels were determined the day before the procedure. The primary endpoint was
restenosis >50%, documented by duplex sonography, at up to 12 months' follow-up. Cox proportional
hazards analysis was used to determine the risk of restenosis in relation to pretreatment homocysteine
levels.Results: The restenosis rate at 12 months was 46%. Median baseline plasma homocysteine levels
were not different in patients with and without restenosis (15.4 versus 16.7 micromol/L, p=0.30).
Compared to patients with homocysteine levels </=14 micromol/L (lower tertile, n=43), the hazard ratio
of incident restenosis was 0.75 (95% CI 0.40 to 1.40) in patients with homocysteine levels from 14.1 to
19.6 micromol/L (middle tertile, n=42) and 0.64 (95% CI 0.33 to 1.22) in patients with homocysteine
levels >/=19.7 micromol/L (upper tertile, n=42) (p=0.38). Multivariate analysis showed that lesion
length (p<0.0001) and lack of hypertension (p=0.0013) were associated with restenosis.Conclusions:
Elevated plasma homocysteine levels are not associated with restenosis after femoropopliteal
angioplasty. Therefore, plasma homocysteine cannot be considered as an important risk factor
influencing the outcome after initially successful angioplasty in femoropopliteal arteries.
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Purpose: To assess the relationship between plasma homocysteine levels and restenosis
after femoropopliteal percutaneous transluminal angioplasty.
Methods: Over a 10-month period, 128 consecutive, symptomatic patients (72 men; me-
dian age 70 years) having successful femoropopliteal angioplasty for atherosclerotic oc-
clusive disease were prospectively enrolled in the study. Plasma homocysteine levels were
determined the day before the procedure. The primary endpoint was restenosis .50%,
documented by duplex sonography, at up to 12 months’ follow-up. Cox proportional haz-
ards analysis was used to determine the risk of restenosis in relation to pretreatment
homocysteine levels.
Results: The restenosis rate at 12 months was 46%. Median baseline plasma homocysteine
levels were not different in patients with and without restenosis (15.4 versus 16.7 mmol/L,
p50.30). Compared to patients with homocysteine levels #14 mmol/L (lower tertile, n543),
the hazard ratio of incident restenosis was 0.75 (95% CI 0.40 to 1.40) in patients with
homocysteine levels from 14.1 to 19.6 mmol/L (middle tertile, n542) and 0.64 (95% CI 0.33
to 1.22) in patients with homocysteine levels $19.7 mmol/L (upper tertile, n542) (p50.38).
Multivariate analysis showed that lesion length (p,0.0001) and lack of hypertension
(p50.0013) were associated with restenosis.
Conclusions: Elevated plasma homocysteine levels are not associated with restenosis after
femoropopliteal angioplasty. Therefore, plasma homocysteine cannot be considered as an
important risk factor influencing the outcome after initially successful angioplasty in fem-
oropopliteal arteries.
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Restenosis remains a major problem after ini-
tially successful angioplasty, occurring in 35%
to 50% of lower limb arteries within 1 year
after the initial angioplasty procedure.1–5
Thus, by necessitating further interventions,
restenosis has not only clinical but also eco-
nomical implications.
The mechanisms of restenosis are complex
and still not completely understood. Reste-
nosis is most commonly secondary to myo-
intimal proliferation, arterial remodeling, and/
or platelet deposition with subsequent re-
lease of platelet derived growth factor.6–11
Many mediators are related to these patho-
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physiological mechanisms and contribute to
the development of restenosis after angio-
plasty of peripheral arteries. One of these me-
diators, hyperhomocysteinemia, is now an ac-
cepted and potentially modifiable risk factor
for cardiovascular disease and death.12–15 Be-
cause endothelial cell damage, vascular
smooth muscle cell (SMC) proliferation, and
thrombus formation after angioplasty could
be influenced by homocysteine, hyperhomo-
cysteinemia might affect the outcome after
percutaneous transluminal angioplasty. Al-
though a significant association between hy-
perhomocysteinemia and outcome after cor-
onary angioplasty has been reported,16–19 the
relationship between hyperhomocysteinemia
and restenosis after initially successful angio-
plasty of peripheral arteries has not yet been
thoroughly investigated. In the present study,
we sought to evaluate whether pretreatment
plasma homocysteine levels are related to
outcome after femoropopliteal angioplasty.
METHODS
Study Design
In a prospective study conducted in accor-
dance with the recommendations of the Dec-
laration of Helsinki and approved by the local
ethics committee, symptomatic patients with
angiographically or sonographically docu-
mented femoropopliteal .50% de novo or re-
current lesions were enrolled if primary fem-
oropopliteal angioplasty (with or without
local thrombolysis and/or thrombus extrac-
tion) was successful. Patients were excluded
(1) if they were taking anticoagulants or med-
ication that affects the homocysteine pathway
(multivitamins, tricyclic antidepressants, car-
bamazepine, levodopa, or phenytoin); (2)
when stent implantation was necessary; (3) if
nonatherosclerotic vascular disease was pres-
ent; (4) if the lesion was in a femoropopliteal
bypass graft; (5) when additional interven-
tions were performed during follow-up; or (6)
if the life expectancy was ,12 months.
Angioplasty was performed with standard
guidewires and balloon catheters; balloon
pressure and inflation duration were left to
the discretion of the operator. A successful
procedure was defined as #30% residual ste-
nosis documented by duplex sonography the
day after the procedure.20,21 Patients were giv-
en 100 mg/d of aspirin starting at least the day
before the procedure if they were not already
on aspirin therapy. Adjunctive drug therapy
(e.g., unfractionated or low-molecular-weight
heparin, locally applied urokinase) was also at
the discretion of the operator.
Patient Sample
Over a 10-month period, 128 consecutive
patients (72 men; median age 70 years) were
enrolled and gave written informed consent
to participate in the study. At entry, the pa-
tient’s age, sex, and vascular risk factors (di-
abetes, hyperlipidemia, hypertension, smok-
ing habits) were recorded, as was current
medication. The patient’s self-reported history
was taken, followed by a clinical examination
(palpation of peripheral pulses, auscultation
of bruits) and noninvasive assessment, in-
cluding pulse volume recordings, and ankle
systolic pressure measurements for calcula-
tion of the ankle-brachial index (ABI) at rest.
The severity of peripheral arterial occlusive
disease was classified using Fontaine stage II
(claudication) or stage III/IV (critical limb is-
chemia with persistently recurrent pain re-
quiring regular analgesia for .2 weeks and/
or ulceration or gangrene of the foot or toes
plus ankle systolic pressure ,50 mmHg).
Characteristics of the lesions to be treated
(stenosis/occlusion) were recorded as docu-
mented by angiography.
Plasma Homocysteine and Other
Laboratory Tests
Fasting venous blood samples were drawn
early on the day before intervention and
processed immediately. Total plasma homo-
cysteine levels were determined using a
chemiluminescence enzyme immunoassay
(ImmuLight 2000; Diagnostic Products Corp.,
Los Angeles, CA, USA). Additional routine
blood tests included measurement of creati-
nine, cholesterol (HDL, LDL), triglycerides,
glycosylated hemoglobin, hematocrit, plate-
lets, and leukocytes using standard estab-
lished laboratory methods.
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Follow-up and Endpoints
Patients were assessed the day after the
procedure and at 1, 3, 6, and 12 months by
taking the history, clinical examination (pal-
pation of peripheral pulses, auscultation of
bruits), pulse volume recordings, ankle sys-
tolic pressure measurement for calculation of
the ABI. The day after the procedure and at 3,
6, and 12 months, color-coded duplex sonog-
raphy of the treated femoropopliteal segment
was performed with a 5-MHz linear probe
(Acuson XP10; Siemens, Mountain View, CA,
USA). Duplex was also performed at any time
during follow-up when restenosis/reocclusion
was suspected due to symptomatology, clin-
ical examination, and/or a .0.15 decrease in
the ABI from the postprocedural value. Peak
systolic velocities (PSV) in the treated seg-
ment and in the proximal normal segment
were measured, and peak velocity ratio (PVR:
PSV in the dilated segment divided by the
proximal PSV) was calculated. A PVR $2.4 in-
dicated a significant ($50%) restenosis at that
site.21
The primary endpoint was restenosis .50%
demonstrated by duplex sonography at up to
12 months. The secondary endpoint was clin-
ical outcome defined as recurrent or in-
creased symptoms.
Statistical Analysis
The calculation of an appropriate sample
size was based on the following statement: if
the probability for a patient with restenosis to
have a higher level of homocysteine than a
patient without restenosis is .0.65, a signifi-
cant difference between the groups will be
detected in .80% of the cases if both groups
contain at least 60 patients.
StatView 5.0 (Abacus Concepts, SAS Insti-
tute, Cary, NC, USA) was used for data man-
agement and analyses. Homocysteine was
examined as a continuous variable and as a
dichotomous variable in tertiles. Continuous
variables are reported as medians and inter-
quartile ranges, categorical variables as
counts and percentages. Intergroup compari-
sons of baseline data were done using the
Wilcoxon rank sum test for continuous vari-
ables and the Fisher exact test for categorical
variables. Differences between the groups ac-
cording to homocysteine tertiles were tested
using the Kruskal-Wallis test for continuous
variables and the chi-square test for categor-
ical variables. Freedom from restenosis ac-
cording to homocysteine in tertiles was plot-
ted as Kaplan-Meier curves; differences
among the groups were analyzed by the log-
rank test.
Cox proportional hazard analysis was used
to determine an association between reste-
nosis and homocysteine in tertiles, express-
ing the results as the hazard ratio (HR) with
95% confidence interval (CI). Multivariate
analysis (stepwise backward) was performed
to take into account the effect of possible con-
founders. All variables that showed baseline
imbalances (p,0.1) between patients with
and without restenosis or according to ho-
mocysteine tertiles were included in the mul-
tivariate model. Significance was defined as
p,0.05.
RESULTS
Over a median 10-month follow-up (IQR 5–
12), 7 (5.5%) patients were lost: 1 at 1 month,
2 at 3 months, 1 at 6 months, and 3 at 12
months. Of those, 1 died of myocardial in-
farction, 2 refused follow-up, and no infor-
mation could be obtained on the remaining 4.
Thus, complete hemodynamic information by
ABI measurements and duplex sonography
was available for analysis in 121 patients.
Baseline characteristics of the patients lost to
follow-up did not differ from patients who
continued throughout the study.
Nearly half (56, 46%) of the 121 patients had
restenosis documented by duplex sonography
at 12 months. Of these, 43 (35%) presented
with new onset or increased symptoms; 50 pa-
tients had a drop in ABI, but 6 had no clinical
symptoms or decrease in ABI. Patients with
restenosis had longer lesions and a lower ABI
at baseline; occlusion was more frequent than
stenosis (Table 1). Hypertension was less com-
mon in patients with restenosis than in those
without restenosis. Pretreatment homocyste-
ine levels were not different in patients with
and without restenosis. Intake of clopidogrel
was more frequent in the restenosis group (11
[19%] versus 4 [6%], p50.02), but there were
J ENDOVASC THER
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TABLE 1
Baseline Characteristics of 121 Patients With Respect to Outcome at 12 Months
No Restenosis
(n565, 54%)
Restenosis
(n556, 46%) p
Men
Age, y
Smoker
Diabetes mellitus
Hypertension
39 (60%)
70 (63–79)
48 (74%)
22 (34%)
57 (88%)
29 (52%)
68 (59–77)
42 (75%)
20 (36%)
39 (70%)
0.46
0.27
0.99
0.85
0.02
Hypercholesterolemia
Previous PTA
Coronary heart disease
Cerebrovascular disease
46 (71%)
25 (38%)
26 (40%)
7 (11%)
40 (71%)
28 (50%)
21 (37%)
19 (34%)
0.99
0.27
0.85
0.12
PAD severity
Stage II
Stage III/IV
Stenosis/occlusion
Stenosis, %
59 (91%)
6 (9%)
41/24 (63%/37%)
80 (80–90)
50 (89%)
6 (11%)
23/33 (41%/59%)
90 (80–90)
0.99
0.01
0.36
Lesion length, cm
0 to 1 / 2 to 3-vessel runoff
ABI at baseline
ABI 1 day after dilation
Homocysteine, mmol/L
4 (1–6)
19/46 (29%/71%)
0.69 (0.57–0.80)
0.90 (0.80–0.96)
16.7 (13.8–22.0)
6 (4–14)
15/41 (27%/73%)
0.60 (0.53–0.72)
0.88 (0.76–0.96)
15.4 (11.1–20.8)
0.0005
0.68
0.021
0.39
0.30
Creatinine, mmol/L
Total cholesterol, mmol/L
HDL-cholesterol, mmol/L
LDL-cholesterol, mmol/L
Triglycerides, mmol/L
95 (78–118)
5.4 (4.6–6.4)
1.45 (1.22–1.69)
3.53 (2.68–4.38)
1.47 (1.07–2.07)
85 (75–101)
5.4 (4.8–6.0)
1.36 (1.13–1.63)
3.54 (2.54–4.25)
1.97 (1.08–2.55)
0.05
0.66
0.36
0.47
0.34
Glycosylated hemoglobin, %
Hematocrit, %
Platelets, 3103/mL
Leukocytes, 3103/mL
PTA/thrombolysis
Residual stenosis, %
0.067 (0.062–0.077)
39.6 (38.4–41.7)
250 (205–300)
7.49 (6.50–8.93)
56/9 (86%/14%)
0 (0)
0.066 (0.061–0.081)
40.2 (36.8–42.3)
253 (203–288)
8.22 (6.33–9.82)
52/4 (93%/7%)
0 (0–30)
0.90
0.81
0.90
0.43
0.37
0.23
l l
Data are given as medians (interquartile ranges) for continuous variables and counts (per-
centages) for categorical variables.
PTA: percutaneous transluminal angioplasty. PAD: peripheral arterial disease, ABI: ankle-
brachial index, LDL: low-density lipoprotein, HDL: high-density lipoprotein.
no differences between the groups concerning
other concomitant medication at discharge
(ACE inhibitors, angiotensin receptor blockers,
beta blockers, statins, oral antidiabetic agents,
insulin, diuretics, allopurinol). All patients were
on aspirin.
Analysis of baseline characteristics accord-
ing to homocysteine levels (Table 2) found
that patients in the upper tertile ($19.7 mmol/
L) had the worse runoff and higher total cho-
lesterol, LDL-cholesterol, and creatinine val-
ues than patients in the middle (14.1 to 19.6
mmol/L) or lower (#14 mmol/L) tertiles. How-
ever, these third-tertile patients had the low-
est rate of restenosis according to the Kaplan-
Meier analysis (Fig. 1), but the differences
among the groups were not statistically sig-
nificant (p50.35). The hazard ratios (95% CI)
of incident restenosis for homocysteine val-
ues in tertiles (lower, middle, upper) as esti-
mated by the univariate Cox proportional haz-
ards model was 1.0, 0.75 (0.40–1.40), and 0.64
(0.33–1.22) (p50.38). Multivariate analysis (Ta-
ble 3) showed that lesion length (p,0.0001)
and lack of hypertension (p50.0013) were as-
sociated with restenosis.
The analysis of hemodynamic outcome
(represented by ABI measurements) to ho-
mocysteine in tertiles (Fig. 2) showed no dif-
ference among the groups in the median ABI
at baseline (p50.49; Table 2). After the pro-
cedure, the ABI (95% CI) rose in all 3 groups:
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TABLE 2
Baseline Characteristics and Laboratory Findings in 128 Patients According to Homocysteine Levels
Lower Tertile*
(n543)
Middle Tertile*
(n542)
Upper Tertile*
(n543) p
Men
Age, y
Smoker
Diabetes mellitus
Hypertension
24 (56%)
66 (59–73)
33 (77%)
14 (33%)
36 (84%)
22 (52%)
74.5 (64–79)
29 (69%)
16 (38%)
31 (74%)
26 (60%)
71 (63–79)
31 (72%)
15 (35%)
36 (84%)
0.75
0.08
0.72
0.86
0.41
Hypercholesterolemia
Coronary heart disease
Cerebrovascular disease
Previous PTA
28 (65%)
16 (37%)
5 (12%)
15 (35%)
30 (71%)
19 (45%)
5 (12%)
22 (52%)
32 (74%)
16 (37%)
8 (19%)
18 (42%)
0.62
0.68
0.57
0.26
PAD severity
Stage II
Stage III/IV
Stenosis/occlusion
Stenosis, %
39 (91%)
4 (9%)
24/19 (56%/44%)
90 (80–90)
39 (93%)
3 (7%)
24/18 (57%/43%)
90 (80–90)
36 (84%)
7 (16%)
21/22 (49%/51%)
80 (80–90)
0.36
0.71
0.93
Lesion length, cm
0 to 1 / 2 to 3-vessel runoff
ABI at baseline
Creatinine, mmol/L
3.5 (1.0–10.0)
13/30 (30%/67%)
0.69 (0.56–0.80)
83 (73–97)
5 (2.5–11.0)
7/35 (17%/81%)
0.64 (0.59–0.78)
84 (77–97)
5 (2–10)
19/24 (44%/56%)
0.59 (0.50–0.77)
106 (86–131)
0.35
0.02
0.49
,0.001
Total cholesterol, mmol/L
HDL-cholesterol, mmol/L
LDL-cholesterol, mmol/L
Triglycerides, mmol/L
Glycosylated hemoglobin, %
5.2 (4.8–6.4)
1.45 (1.24–1.73)
3.47 (2.72–4.28)
1.59 (1.11–2.67)
0.067 (0.061–0.084)
5.1 (4.2–5.7)
1.48 (1.11–1.78)
3.27 (2.66–3.89)
1.73 (1.06–2.43)
0.066 (0.062–0.079)
5.6 (5.0–6.5)
1.33 (1.12–1.52)
4.01 (3.39–4.71)
1.67 (1.03–2.18)
0.070 (0.064–0.074)
0.04
0.11
0.005
0.93
0.99
Hematocrit, %
Platelets, 3103/mL
Leukocytes, 3103/mL
PTA/thrombolysis
Residual stenosis, %
40.0 (38.9–41.6)
252 (219–291)
7.00 (6.28–9.00)
40/3 (93%/7%)
0 (0)
39.7 (36.3–41.9)
239 (198–297)
7.68 (6.44–9.80)
37/5 (88%/12%)
0 (0–30)
39.2 (37.7–44.0)
263 (215–297)
7.67 (6.47–9.55)
37/6 (86%/14%)
0 (0)
0.69
0.51
0.42
0.56
0.90
l l
Data are given as medians (interquartile ranges) for continuous variables and counts (percentages) for categorical
variables.
PTA: percutaneous transluminal angioplasty. PAD: peripheral arterial disease, ABI: ankle-brachial index, LDL: low-
density lipoprotein, HDL: high-density lipoprotein.
* Lower tertile (#14 mmol/L): homocysteine median 10.8 mmol/L (10.3–12.7), middle tertile (14.1–19.6 mmol/L): me-
dian 15.9 mmol/L (15.2–17.6), upper tertile ($19.7 mmol/L): median 24.6 mmol/L (21.3–31.0).
Figure 1lKaplan-Meier curves for freedom from
restenosis after femoropopliteal angioplasty ac-
cording to homocysteine levels (in tertiles).
from 0.69 (0.6–0.73) to 0.89 (0.82–0.93) in the
lower, from 0.64 (0.61–0.69) to 0.89 (0.81–0.93)
in the middle, and from 0.59 (0.55–0.69) to
0.90 (0.82–0.95) in the upper tertile. Median
ABI values in the lower, middle, upper tertiles,
respectively, were 0.86 (0.78–0.96), 0.91 (0.80–
0.94), and 0.89 (0.82–0.98) at 3 months; 0.85
(0.77–0.95), 0.80 (0.74–0.91), and 0.76 (0.66–
0.86) at 6 months; and 0.87 (0.79–0.92), 0.86
(0.77–0.91), and 0.92 (0.78–0.99) at 12 months.
DISCUSSION
Several studies have shown that elevated
plasma homocysteine is an independent risk
factor for the development of atherosclerosis
in the coronary, cerebral, and peripheral vas-
J ENDOVASC THER
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TABLE 3
Multivariate Cox Proportional Hazards Analysis Showing the Risk of Restenosis
According to Homocysteine Levels and Other Possible Predictors
Hazard Ratio
95% Confidence
Interval p
Homocysteine (in tertiles)
Lower (#14 mmol/L)
Middle (14.1–19.6 mmol/L)
Upper ($19.7 mmol/L)
1.0
0.72
0.47
—
0.34 to 1.52
0.19 to 1.19
0.27
—
0.39
0.11
Hypertension–No*
Lesion length*
Stenosis/occlusion
Runoff
ABI at baseline
3.18
1.04
0.70
1.08
0.20
1.52 to 6.62
1.00 to 1.09
0.31 to 0.56
0.42 to 2.74
0.02 to 1.73
0.002
0.01
0.38
0.86
0.14
Creatinine
Age
Total cholesterol
LDL-cholesterol
0.99
0.99
1.08
1.14
0.97 to 1.01
0.96 to 1.02
0.42 to 2.75
0.42 to 3.09
0.50
0.69
0.86
0.78
l l
ABI: ankle-brachial index, LDL: low-density lipoprotein.
* Stepwise backward: lesion length: HR 1.05, p,0.0001; no hypertension: HR 2.89,
p50.0013.
Figure 2lAnkle-brachial indices (ABI) after femoropopliteal angioplasty with respect to ho-
mocysteine levels (in tertiles).
culature12,13 and is a strong predictor of rest-
enosis after coronary angioplasty.16,17 Since
homocysteine promotes SMC proliferation,
arterial remodeling, and platelet deposition,
all of which are involved in the cascade of
pathogenic mechanisms leading to restenosis
after catheter-based interventions, we hy-
pothesized that elevated plasma homocyste-
ine levels could also be predictive of postan-
gioplasty restenosis in the peripheral vessels.
Surprisingly, our prospective study found no
such association between baseline plasma
homocysteine levels and restenosis after fem-
oropopliteal angioplasty over at 12-month ob-
servation period.
In an earlier work, Tsakiris and coworkers11
presented the same lack of association be-
tween preangioplasty homocysteine levels
and outcome during a 6-month follow-up.
Their study, done in a smaller number of pa-
tients over a shorter follow-up than ours, had
been designed to investigate the relationship
between cell adhesion molecules and out-
come after angioplasty. However, no correla-
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tion between homocysteine and those acti-
vation markers was found. Our study, on the
other hand was designed specifically to as-
sociate pretreatment plasma homocysteine
levels with outcome after femoropopliteal an-
gioplasty in a larger cohort.
The surprising divergence in our results for
peripheral angioplasty compared to coronary
interventions might possibly be explained by
differences in the pathophysiological mecha-
nisms underlying atherosclerosis in general
and restenosis in particular in the coronary
versus femoropopliteal arteries. Increasing
evidence suggests that adverse vascular ef-
fects of homocysteine are mainly mediated
through impaired endothelium-dependent, ni-
tric oxide–mediated vasodilation.22,23 An ana-
tomical heterogeneity of endothelial dysfunc-
tion has been shown in the setting of vascular
aging using a mammalian model.24 If the
same mechanism were applicable to humans,
then these anatomical variations may, at least
partly, account for the differences observed
between peripheral and coronary angioplasty
regarding the potential underlying harmful ef-
fects of hyperhomocysteinemia. This expla-
nation is further strengthened by the fact that
most patients undergoing angioplasty in our
study were older.
The exact mechanism of hyperhomocystei-
nemia-induced endothelial dysfunction is still
not completely understood. However, it has
been suggested that increased oxidative dam-
age might be involved.25 In most patients, fol-
ic acid alone or in combination with vitamin
B6 and B12 has been shown to be effective in
reducing homocysteine plasma concentra-
tions26 and to effectively reduce oxidative
stress markers.27 Although folate treatment to
lower plasma levels of homocysteine has pre-
viously been shown to significantly reduce
the rate of restenosis after coronary angio-
plasty,18 one may question whether the as-
sociation of high homocysteine levels and
greater incidence of restenosis after coronary
angioplasty reflects causality. Folic acid may
also exert its beneficial effects through mech-
anisms independent of homocysteine lower-
ing. However, if hyperhomocysteinemia were
to be causally involved, then, based on our
current data, its treatment will be of no effect
in the setting of peripheral angioplasty.
A limitation of our study is its focus on pa-
tients with primarily successful angioplasty;
patients with dilation failure or stent implan-
tation, who might have more extensive dis-
ease, were excluded. Further limitations are
the small sample size and the lack of homo-
cysteine data during follow-up. However, ho-
mocysteine values at 12 months were avail-
able in a small subgroup of patients (n530):
analyzing these data, we found no difference
between homocysteine levels at baseline and
at 12 months; furthermore, we found no dif-
ference in homocysteine levels at 12 months
between patients without and with restenosis.
In conclusion, our data suggest that elevat-
ed plasma homocysteine levels are not as-
sociated with restenosis after femoropopliteal
angioplasty. Therefore, therapies solely de-
signed to reduce plasma homocysteine levels
will be useless in this particular pathophysi-
ological context.
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